Loading
PTPRT (Receptor-type tyrosine-protein phosphatase T) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and 5 more.
May be involved in both signal transduction and cellular adhesion in the CNS.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming JSI-124 and Stattic. Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes literature 0.94, animal model 0.62, genetic association 0.32, somatic mutation 0.90). IntOGen calls it a driver in 8 cohorts (7 activating, 1 loss-of-function), covering Oesophageal Adenocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Ovarian Epithelial Tumour, Pancreatic Adenocarcinoma and others.
In plain words · PTPRT (Receptor-type tyrosine-protein phosphatase T) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and 5 more.
PTPRT (Receptor-type tyrosine-protein phosphatase T) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and 5 more.
May be involved in both signal transduction and cellular adhesion in the CNS. Location: Membrane (UniProt).
No product in this corpus aims at PTPRT yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA PTPRT: RNA tissue enhanced (brain 14 nTPM, fallopian tube 10 nTPM, lymphoid tissue 6 nTPM); high antibody staining in 1 normal tissue; highest cancer staining carcinoid (1 of 4 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Head and neck squamous cell carcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Hepatocellular carcinoma, Pancreatic ductal adenocarcinoma, Skin cancer (all types) and more); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt O14522; CIViC gene PTPRT; IntOGen PTPRT; Human Protein Atlas PTPRT tissue; Open Targets ENSG00000196090 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Ohara et al, DNA Res, 1997, "Construction and characterization of human brain cDNA libraries suitable for analysis of cDNA clones encoding relatively large proteins". Source.
Sources: HGNC HGNC:9682 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O14522 (protein name, function text, keywords and locations (REST API)); CIViC gene PTPRT (1 evidence items, 0 assertions, 1 variants; diseases: Head And Neck Squamous Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000196090 (association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: gastric cancer 0.54, oesophageal cancer 0.54, ovarian cancer 0.50, melanoma 0.59, thyroid cancer 0.52, neuroendocrine neoplasm 0.52 (GraphQL API, CC0)); IntOGen PTPRT (driver in 8 cohorts (Act 7, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
May be involved in both signal transduction and cellular adhesion in the CNS. Location: Membrane (UniProt). Locus 20q12-q13.11 (HGNC).
RNA: tissue enhanced (brain 14 nTPM, fallopian tube 10 nTPM, lymphoid tissue 6 nTPM), detected in some normal tissues.
Medium: Caudate, Cerebellum, Duodenum, Gallbladder, Hippocampus, Oral mucosa, Rectum, Seminal vesicle.
RNA group enriched: Breast Invasive Carcinoma 9 pTPM, Prostate Adenocarcinoma 3 pTPM.
Medium only: breast cancer, cervical cancer, colorectal cancer, glioma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PTPRT" OR ABSTRACT:"PTPRT" OR TITLE:"protein tyrosine phosphatase receptor type T" OR ABSTRACT:"protein tyrosine phosphatase receptor type T" OR TITLE:"Receptor-type tyrosine-protein phosphatase T" OR ABSTRACT:"Receptor-type tyrosine-protein phosphatase T" OR TITLE:"RPTPrho" OR ABSTRACT:"RPTPrho" OR TITLE:"KIAA0283" OR ABSTRACT:"KIAA0283") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTPRT, not a curated reading list.